Stuart Therapeutics Inc., a privately held ophthalmology biotechnology company based in Florida, has submitted an investigational new drug application amendment to the U.S. Food and Drug Administration to evaluate ST-100 (vezocolmitide), its investigational collagen mimetic peptide ophthalmic solution, for corneal wound healing. Announced on October 9, 2026, the programme represents the company’s first planned clinical expansion of ST-100 beyond dry eye disease, with an initial proof-of-concept study intended to precede a Phase 2 trial in the second half of 2027.
The development introduces a distinct clinical objective for ST-100, which Stuart Therapeutics is developing to target damaged helical collagen in the extracellular matrix of ocular tissues. Rather than focusing exclusively on dry eye symptoms and associated ocular surface damage, the new programme will investigate whether the candidate can support healing of the corneal epithelium and stroma following tissue injury. The planned development population includes wounds associated with trauma, surgery, corneal ulcers and chemical burns, although the exact populations and trial design have not yet been publicly detailed.
The expansion is supported by preclinical research showing that collagen mimetic peptides can influence corneal epithelial regeneration, alongside human dry eye studies that have produced mixed efficacy findings. Stuart Therapeutics has reported improvements in several ocular surface measures during previous trials, but its initial Phase 3 study did not achieve statistical significance on the prespecified primary tear-production endpoint. Consequently, the corneal wound programme offers an additional opportunity to investigate the underlying therapeutic approach while creating a separate clinical development requirement for a new indication.
The regulatory distinction is important because submission of an investigational new drug amendment is not marketing approval and does not establish that the proposed treatment works for corneal wounds. The announcement also does not confirm that the planned proof-of-concept investigation has enrolled patients or generated clinical results. Its significance lies in the movement of a previously researched collagen-targeting technology toward a potentially broader clinical application, with human wound-healing evidence still required.
How does ST-100’s collagen mimetic peptide technology aim to repair damaged corneal tissue?
ST-100 is based on Stuart Therapeutics’ proprietary PolyCol platform, which uses collagen mimetic peptides designed to interact with damaged helical collagen structures. Collagen is an essential component of the corneal extracellular matrix, helping maintain tissue integrity and providing a structural environment for cellular attachment and repair. The company’s therapeutic hypothesis is that selectively targeting damaged collagen could help restore the conditions needed for epithelial regeneration and normal cellular signalling, potentially addressing tissue damage through a mechanism different from conventional ocular surface treatments.
The scientific rationale has been investigated in preclinical research, including a 2021 study published in Frontiers in Pharmacology examining collagen mimetic peptides in models of corneal epithelial injury. Researchers found that treatment improved the alignment of experimentally damaged collagen fibers and accelerated corneal epithelial wound closure in mice compared with vehicle treatment. The experiments also identified improvements in epithelial cell density and attachment to underlying tissue, supporting further investigation of the relationship between collagen integrity and surface regeneration.
The animal findings are particularly relevant because the new programme concerns physical injury to the cornea rather than dry eye symptoms alone. However, the laboratory study used controlled experimental injuries, and its observations over approximately 24 hours cannot establish how quickly an equivalent treatment would heal complex human wounds. Corneal ulcers, chemical injuries and surgical trauma involve different mechanisms of tissue damage, and some may include infection, inflammation, nerve dysfunction or extensive stromal injury that cannot be addressed through collagen repair alone.
Additional preclinical research published in 2023 examined collagen mimetic peptide treatment in a mouse model of dry eye-associated corneal nerve damage. The investigators reported reduced nerve fragmentation, improved neuronal coverage and improvements in epithelial integrity and tear-related measures compared with vehicle controls. These findings strengthen the biological rationale for exploring ocular tissue restoration, but they do not establish that ST-100 restores damaged human corneal nerves or prevents vision loss after injury.
What do the Phase 2 and Phase 3 dry eye results reveal about ST-100’s clinical evidence?
Stuart Therapeutics’ existing human development programme provides useful evidence of ST-100’s activity on the ocular surface, although its results require careful interpretation. A randomized, double-masked Phase 2 trial enrolled 160 patients with dry eye disease and evaluated two concentrations of ST-100 against vehicle over approximately four weeks. The study assessed corneal fluorescein staining, ocular discomfort and tear production, providing several measurements of ocular surface function rather than relying on symptoms alone.
The peer-reviewed Phase 2 publication reported that the high-dose formulation produced a statistically significant improvement in Schirmer’s tear test measurements compared with vehicle, with a least-squares mean difference of 2.3 millimetres and a p-value of 0.0094. The proportion of patients achieving at least a 10-millimetre improvement in the Schirmer test was 12.2% in the high-dose group compared with 0% in the vehicle group, with a reported p-value of 0.0266. These findings supported further development, although the prespecified primary corneal staining endpoint in the study eye did not demonstrate superiority over vehicle.
The distinction is important when assessing claims about the candidate’s ability to accelerate tissue repair. The Phase 2 study reported favourable findings on selected staining measures when both eyes were analysed together, but that result did not negate the failure of the prespecified study-eye staining endpoint. Ocular discomfort improved within treatment groups, yet the primary symptom comparison also did not establish superiority over vehicle. The published results therefore support evidence of activity on particular measures without demonstrating consistent success across all primary efficacy outcomes.
The subsequent Phase 3 trial introduced another important limitation. In June 2025, Stuart Therapeutics reported that ST-100 had failed to achieve statistical significance on its primary endpoint, the proportion of patients demonstrating a greater than 10-millimetre improvement from baseline in Schirmer’s tear testing after 29 days. The company attributed the outcome partly to stronger vehicle-group performance than observed in the earlier study, while reporting statistically significant improvements in selected corneal fluorescein staining measurements and visual function assessments.
Those secondary findings remain relevant to the new corneal wound programme because they involve ocular surface measurements, but they are not equivalent to proof of wound-healing efficacy. Corneal fluorescein staining measures surface abnormalities and can reflect tissue damage, whereas clinical wound healing may require evidence of complete and sustained epithelial closure, stromal recovery and the absence of complications. The initial Phase 3 primary endpoint failure also means that positive secondary findings cannot be presented as an overall successful confirmatory trial.
Stuart Therapeutics is planning another Phase 3 registration study in dry eye disease for early 2027, with earlier company communications identifying the next programme as Phase 3b. That study will be important for determining whether the observed secondary efficacy signals can translate into a stronger confirmatory evidence package. At the same time, the corneal wound programme will need to establish its own clinical efficacy rather than relying on the results obtained in patients with dry eye disease.
Why could corneal ulcers, surgery and chemical burns present very different challenges for ST-100?
The proposed wound-healing programme covers several clinically distinct forms of corneal injury, creating both an opportunity for broad development and a potential complication for trial design. A superficial epithelial defect following an ophthalmic procedure may have a substantially different healing pattern from an infected corneal ulcer or a severe chemical burn involving deeper tissues. Although damaged collagen may be relevant across these conditions, its contribution to impaired healing can vary alongside infection, inflammation, tissue loss, tear film abnormalities and limbal stem cell dysfunction.
A persistent corneal epithelial defect is generally characterised by failure of the corneal surface to heal despite appropriate treatment, often over a period of approximately two weeks. A 2025 review in the journal Vision described the limitations of existing approaches and the growing interest in therapies that encourage epithelial regeneration. The review identified several emerging treatments being investigated for persistent defects, while emphasising that effective management also depends on addressing the underlying cause of the injury.
For ST-100, the choice of the first human wound-healing population may have considerable influence on the development programme’s ability to generate interpretable results. A relatively defined injury type could allow researchers to measure healing consistently, whereas combining chemically induced damage, surgical wounds and infectious ulcers could introduce important differences in baseline severity and recovery. Such differences may affect the interpretation of efficacy even if the investigational treatment produces a measurable biological effect in selected patients.
Future trials may need to assess endpoints such as time to complete epithelial closure, the proportion of wounds that heal within a defined period and the durability of closure after treatment. Additional assessments could include recurrent epithelial breakdown, corneal clarity, scarring, visual function and the need for further intervention, depending on the population selected. The company has not yet disclosed sufficient details to establish which outcomes will serve as primary endpoints in the planned proof-of-concept and Phase 2 investigations.
How would ST-100 compete with existing corneal wound treatments and emerging regenerative therapies?
Current management of corneal wounds includes a combination of treatments selected according to the injury’s underlying cause, severity and location. These may include lubrication, protective contact lenses, antimicrobial treatment where indicated, biological surface-support approaches and surgical interventions for more serious or persistent defects. The therapeutic objective is not limited to epithelial closure because successful recovery may also require infection control, restoration of tissue integrity and preservation of vision.
Stuart Therapeutics believes that a topical medicine designed to repair damaged collagen could offer a differentiated approach by acting on the extracellular matrix supporting the corneal surface. President and Chief Executive Officer Eric Schlumpf has positioned the programme around the possibility of addressing structural tissue damage associated with trauma, surgery and chemical injury. However, the existence of a proposed collagen-targeting mechanism does not establish that ST-100 will outperform established treatment approaches or provide benefits across every type of corneal wound.
There are also approved therapies for particular corneal disorders that demonstrate why precise indication boundaries are essential. Dompé’s Oxervate, containing cenegermin, is approved in the United States for neurotrophic keratitis, a condition associated with impaired corneal nerve function and abnormal surface healing. Its regulatory indication does not cover corneal injuries generally, while its nerve growth factor mechanism differs from Stuart Therapeutics’ proposed collagen mimetic approach.
Other experimental approaches to persistent epithelial defects include growth factor-related treatments, biological preparations, peptide-based therapies and technologies designed to support epithelial regeneration. Some are intended for specific causes of non-healing wounds, while others are being evaluated across broader ocular surface disorders. If ST-100 eventually demonstrates clinical efficacy, its competitive positioning will depend on the population studied, magnitude of healing improvement, tolerability, dosing requirements and whether it can be incorporated into existing clinical workflows.
What must the FDA amendment and 2027 clinical programme establish before ST-100 can advance?
The October 2026 announcement confirms that Stuart Therapeutics has submitted an investigational new drug application amendment seeking to evaluate ST-100 in corneal wound healing. This is a development-stage regulatory action and should not be confused with approval of the new indication or confirmation that the planned study has started. The company has not publicly provided a detailed protocol covering patient numbers, randomisation, comparator, treatment duration or the complete efficacy and safety endpoint structure.
The proposed proof-of-concept study should provide an opportunity to investigate whether the biological activity observed in experimental models is reproducible in human corneal wounds. Depending on its design, the study may also help identify a suitable patient population, practical dosing regimen and the most informative wound-healing measurements. These findings could guide the larger Phase 2 programme that Stuart Therapeutics plans to initiate during the second half of 2027.
Safety evaluation will be particularly relevant because the investigational use involves already damaged ocular tissues. A formulation that has been studied in dry eye disease cannot automatically be assumed to have the same tolerability profile in patients with open epithelial defects, deeper corneal injuries or severe inflammation. Clinical investigators will need to assess local tolerability, treatment-related complications and the interaction between investigational treatment and the standard care required for the underlying injury.
The company will also need to distinguish improvements in wound appearance from sustained tissue recovery. A reduction in fluorescein staining or wound area may provide an encouraging early signal, but durable epithelial closure and the prevention of recurrent injury could be more relevant in patients with persistent defects. The strength of the eventual evidence will depend on whether trial outcomes demonstrate benefits beyond natural healing and the effects of concurrent treatment.
How does the corneal wound programme fit Stuart Therapeutics’ wider ophthalmology pipeline strategy?
The addition of corneal wound healing gives Stuart Therapeutics another possible clinical application for its PolyCol platform while retaining ST-100 as the central investigational asset. The company has described a portfolio of more than 400 collagen mimetic peptide sequences that could potentially be investigated across several ophthalmic indications. Its broader research interests include glaucoma, myopia and retinal disorders, but those programmes remain separate from the established clinical development of ST-100 in dry eye disease.
This platform structure could offer commercial advantages if a common scientific approach proves effective across more than one indication. However, developing multiple uses for an investigational medicine also creates additional demands on clinical resources, regulatory planning, manufacturing and financing. Each proposed indication must be supported by an appropriate evidence package, and favourable results in one disease cannot automatically be transferred to another.
Stuart Therapeutics has strengthened its leadership and commercial planning capabilities during 2026. In August, the company appointed David Jakeman as Chief Financial Officer, drawing on his experience in biotechnology financial operations and capital-related activities. It also appointed former Allergan executive Dave LeCause as senior commercial advisor, positioning the business for a potential transition toward commercial readiness if its late-stage clinical programme succeeds.
The appointments are commercially relevant because preparing for late-stage ophthalmology development requires more than generating clinical data. Companies must develop the financial systems, regulatory capabilities, manufacturing arrangements and market-access strategies required to support eventual product introduction. Stuart Therapeutics has not disclosed sufficient current financial information in the October announcement to determine the funding coverage available for its proposed dry eye and corneal wound studies.
Because Stuart Therapeutics is privately held, there is no directly traded company stock through which to assess an immediate public-market reaction to the corneal wound announcement. The programme’s commercial significance therefore rests on its scientific progress, ability to attract development support and eventual clinical differentiation rather than a short-term share-price movement. Its near-term priorities remain the planned dry eye registration study and the generation of initial human evidence in corneal wound healing.
What will determine whether ST-100 becomes a viable treatment for corneal wound healing?
The next stage of development will need to convert Stuart Therapeutics’ collagen-repair hypothesis into measurable clinical findings in patients with damaged corneas. The strongest existing support comes from preclinical studies demonstrating effects on collagen alignment, epithelial regeneration and related ocular structures, while the human dry eye programme provides evidence of activity that has not translated consistently into successful primary endpoints. That combination supports further investigation but leaves substantial uncertainty about efficacy in the newly proposed indication.
The company’s development plans establish two significant clinical priorities for 2027. One is the planned Phase 3 registration programme in dry eye disease, which will test whether ST-100 can produce more convincing confirmatory evidence in its original target population. The other is the corneal wound programme, which is expected to progress through proof-of-concept investigation toward a Phase 2 study in the second half of the year.
For clinicians, the most informative development would be evidence that ST-100 meaningfully improves wound closure or recovery beyond existing care without introducing unacceptable ocular risks. For Stuart Therapeutics, a positive proof-of-concept result could justify more focused development in selected corneal injury populations and provide an additional route for advancing its PolyCol platform. Neither outcome is established by the October FDA amendment, and both remain dependent on future clinical findings.
The programme therefore represents a meaningful pipeline expansion without yet constituting a demonstrated therapeutic breakthrough. Stuart Therapeutics has identified a plausible biological target, generated supporting laboratory evidence and gained experience testing its lead candidate in humans, but the next studies will need to establish whether collagen-directed treatment delivers clinically meaningful benefits in injured corneal tissue. The planned 2027 investigations will be the first important opportunity to determine whether that approach can progress from experimental promise toward a distinct ophthalmic treatment application.
